You searched for "learning"

3209 results found

Photophobia: an unusual symptom of a pituitary macroadenoma

Introduction Photophobia, defined as ‘an abnormal intolerance to light’, is commonly associated with a range of both ocular and neurological pathologies such as dry eye, blepharospasm, corneal pathologies, cataracts, uveitis, retinal dystrophies, optic neuritis, migraine, meningitis, and traumatic brain injury...

Verteporfin shortage: treatment options and outcomes in chronic non-resolving central serous chorioretinopathy

Half-dose photodynamic therapy (HD-PDT) with verteporfin has been the therapy of choice in non-resolving central serous chorioretinopathy lasting longer than four months. Since 2021, a worldwide shortage of verteporfin due to manufacturing issues prompted adjustments in treatment practices. This retrospective,...

Haag-Streit launches 5th ‘Slit Lamp Imaging Competition’

Haag-Streit UK (HS-UK), the leading manufacturer and distributor of gold-standard diagnostic and surgical devices and instruments for ophthalmologists, optometrists, and orthoptists, is delighted to announce the launch of the ‘Slit Lamp Imaging Competition 2023’.

‘Phaco-plus’ procedures at forefront of modern glaucoma management

Glaucoma and cataract increasingly present as a ‘two-in-one’ surgical opportunity. In the UK, new modelling suggests ~1 million adults aged ≥40 may currently have glaucoma, with a projected rise to ~1.6 million by 2060 as the population ages and demographics...

Global Experts Unite: Visionary Horizons Sets the Stage for the Future of Ophthalmology

Heidelberg Engineering, as part of EssilorLuxottica, marked a milestone in global eyecare innovation with the inaugural Visionary Horizons symposium — the first event of its kind showcasing Heidelberg’s pioneering innovation and expertise as a driving force within EssilorLuxottica’s technological and...

What's trending Dec/Jan 2021

A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #threeblindmice US company Nanoscope Therapeutics has developed a new treatment which is hoped will restore vision in those affected by retinal...

PRN Ranibizumab verses continuous aflibercept in UK clinical practice

This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...

SightCare wins Service Excellence Award at INSPIRE Business Awards 2024

We are thrilled to announce that SightCare has won the Service Excellence Award at the Inspire Awards 2024! SightCare was selected by the judges because it was felt that “they were pushing the boundaries and trying to move the business...

Case series of toxic anterior segment syndrome

Herein we report two cases of toxic anterior segment syndrome (TASS) following uneventful cataract surgery. Both patients presented 24 hours after their uneventful operations with painless blurred vision in the operated eye. The inflammatory reaction was controlled successfully with an...

Seeing things from down under: Reflecting on an ophthalmology elective in New Zealand

During March 2025, I undertook a four-week elective in ophthalmology at Christchurch Hospital, New Zealand. Having had minimal exposure to ophthalmology within my time at university, I was excited to be further immersed in it whilst also having the opportunity...

Artificial intelligence in glaucoma: Assessing applications instead of technology

Much is said about the potential of artificial intelligence (AI) to transform clinical practice, particularly with the advent of foundation models [1]. The newest models are ‘pretrained’ on text, image, tabular and other forms of data to produce architectures that...

Demystifying external trainee selected components and out of programme experiences

If you don’t know your external TSCs from your OOPC/OOPT/OOPE/OOPR, then this article is for you. Trainee selected components (TSC) are College-approved periods of training, usually ranging from six months to a year (formally ASTO) of intensive subspecialty training in...